Zenas BioPharma, Inc. ZBIO · Stock Open Zenas BioPharma, Inc. in new tab
Analyst price targets
Recent rating changes, newest first
Zenas BioPharma, Inc. Analysis (ZBIO)
Is Zenas BioPharma, Inc. a good investment? Zenas BioPharma, Inc. (ZBIO) is currently trading at 26.87 USD. Market analysts have a consensus price target of 47.88 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 1.68. This relatively low multiple may signal that Zenas BioPharma, Inc. is undervalued compared to historical market norms.
Earnings Schedule: Zenas BioPharma, Inc. is expected to release its next earnings report on Nov. 18, 2026. The market consensus estimate for Forward EPS is -4.66.
Investor FAQ
Does Zenas BioPharma, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Zenas BioPharma, Inc.?
Zenas BioPharma, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 18, 2026. The company currently has a trailing EPS of -9.63.
Company Profile
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Community Discussion